Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Bryostatin in Multiple Sclerosis
NCT06190912Phase 1Terminated
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bryostatin-1 in multiple sclerosis (MS). Primary endpoints: Adverse Events at 37 weeks, Study Medication Discontinuation at 37 weeks and 1 more. Started Jun 2024; status: terminated.
02
Drugs
bryostatin-1
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06190912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190912.